DermTech, Inc's licensee, DermTech Canada Inc., has received approval to market DermTech’s Pigmented Lesions Assay (PLA) and non-invasive biopsy kit for the detection of melanoma in Canada. DermTech Canada will market and sell the PLA, and samples will be processed at DermTech’s central laboratory in La Jolla, CA. Provincial coverage approvals are in process, initially focused on British Columbia and Ontario, and are expected to expand across Canada.
“Health Canada’s approval of the license to market our assay in Canada is a further validation of the utility of our cancer detection platform and a strong statement about the potential demand for a non-invasive alternative to surgical biopsies. We will be working closely with our Canadian licensee to leverage our sales and marketing expertise ensuring a successful launch across Canada,” stated Dr. John Dobak, CEO of DermTech, Inc.
“We are very excited to receive such rapid approval from Health Canada and are enthusiastic about our upcoming Canada-wide launch to bring DermTech’s important new cancer diagnostic to Canadian patients. We look forward to working closely with the DermTech US team to make this roll-out a success,” said Douglas Horne, CEO of DermTech Canada Inc.
For additional information visit: dermtech.com.Next Story